Demographic and clinical characteristics of the study population. BMI: body mass index; PVHT: portal vein hypertension.
 |
| |||
Demographic and clinical characteristics of the study population. BMI: body mass index; PVHT: portal vein hypertension.
| Serotype | TOTAL N = 283 | p | ||
|---|---|---|---|---|
| HBe-positive N = 119 | HBe-negative N = 164 | |||
| Age (years)
Mean ± SD Median [Range] |
38.6 ±14.0 36.0 [18.0 – 82.0] |
46.1 ±12.9 46.0 [20.0 – 83.0] |
42.9 ±13.9 42.0 [18.0 – 83.0] |
<0.001 |
| Gender
Male Female |
92 (77.3%) 27 (22.7%) |
129(78.7%) 35 (21.3%) |
221 (78.1%) 62 (21.9%) |
0.787 |
| BMI
Mean ± SD Median [Range] |
23.8 ±4.0 23.2 [16.0 – 43.0] |
24.7 ±4.2 24.1 [16.7 – 45.0] |
24.3 ±4.1 23.7 [16.0 – 45.0] |
0.036 |
| Place of birth
France/Northern Europe Mediterranean Basin Asia Africa North America |
55 (47.0%) 11 (9.4%) 36 (30.8%) 13(11.1%) 2 (1.7%) |
60 (37.0%) 42 (25.9%) 19(11.7%) 37 (22.8%) 4 (2.5%) |
115(41.2%) 53(19.0%) 55(19.7%) 50(17.9%) 6 (2.2%) |
<0.001 |
| Alcohol consumption
Subjects regularly consuming Daily dose (g/day): mean ± SD |
8 (6.8%) 31.3 ±24.2 |
21 (12.8%) 18.9 ±15.9 |
29(10.3%) 22.6 ±19.1 |
0.100 0.146 |
| Risk factors
None Intravenous drug use At-risk sexual habits Travel to at-risk areas Familial contamination Perinatal contamination |
14(11.8%) 2 (1.7%) 17(14.3%) 49 (41.2%) 40 (33.6%) 41 (34.5%) |
33(20.1%) 1 (0.6%) 7 (4.3%) 74(45.1%) 55 (33.5%) 42 (25.6%) |
47(16.6%) 3(1.1%) 24 (8.5%) 123(43.5%) 95 (33.6%) 83 (29.3%) |
0.062 0.574 0.003 0.509 0.989 0.107 |
| Disease duration (years)
Mean ± SD Median [Range] |
5.8 ±6.0 4.3 [0.1 – 30.8] |
6.7 ±7.5 3.8 [0.1 – 41.7] |
6.3 ±6.9 4.0 [0.1 – 41.7] |
0.809 |
| Symptom presentation
Asthenia Anorexia Weight loss Jaundice Hepatomegaly Ascites Other PVHT symptom |
41 (34.5%) 9 (7.6%) 6 (5.0%) 3 (2.5%) 6 (5.0%) 3 (2.5%) 5 (4.2%) |
75 (45.7%) 7 (4.3%) 11 (6.7%) 5 (3.0%) 18(11.0%) 3 (1.8%) 10(6.1%) |
116(41.0%) 16(5.7%) 17(6.0%) 8 (2.8%) 24 (8.5%) 6(2.1%) 15(5.3%) |
0.057 0.236 0.561 1.000 0.077 0.699 0.482 |
| Other viral liver infections
Hepatitis C Hepatitis D |
0 (0.0%) 2 (1.7%) |
1 (0.6%) 1 (0.6%) |
1 (0.4%) 3(1.1%) |
1.000 0.574 |